Advertisement

Journal of Assisted Reproduction and Genetics

, Volume 36, Issue 2, pp 349–359 | Cite as

Evaluation of Z-VAD-FMK as an anti-apoptotic drug to prevent granulosa cell apoptosis and follicular death after human ovarian tissue transplantation

  • Maïté Fransolet
  • Laure Noël
  • Laurie Henry
  • Soraya Labied
  • Silvia Blacher
  • Michelle Nisolle
  • Carine MunautEmail author
Fertility Preservation

Abstract

Purpose

To evaluate the efficiency of ovarian tissue treatment with Z-VAD-FMK, a broad-spectrum caspase inhibitor, to prevent follicle loss induced by ischemia/reperfusion injury after transplantation.

Methods

In vitro, granulosa cells were exposed to hypoxic conditions, reproducing early ischemia after ovarian tissue transplantation, and treated with Z-VAD-FMK (50 μM). In vivo, cryopreserved human ovarian fragments (n = 39) were embedded in a collagen matrix containing or not Z-VAD-FMK (50 μM) and xenotransplanted on SCID mice ovaries for 3 days or 3 weeks.

Results

In vitro, Z-VAD-FMK maintained the metabolic activity of granulosa cells, reduced HGL5 cell death, and decreased PARP cleavage. In vivo, no improvement of follicular pool and global tissue preservation was observed with Z-VAD-FMK in ovarian tissue recovered 3-days post-grafting. Conversely, after 3 weeks of transplantation, the primary follicular density was higher in fragments treated with Z-VAD-FMK. This improvement was associated with a decreased percentage of apoptosis in the tissue.

Conclusions

In situ administration of Z-VAD-FMK slightly improves primary follicular preservation and reduces global apoptosis after 3 weeks of transplantation. Data presented herein will help to guide further researches towards a combined approach targeting multiple cell death pathways, angiogenesis stimulation, and follicular recruitment inhibition.

Keywords

Fertility preservation Apoptosis Granulosa cells Ovarian tissue transplantation Z-VAD-FMK 

Notes

Acknowledgments

The authors thank the CPMA-CHR Citadelle Liège for their contribution to follicular fluids collection. The authors are very grateful to M. C. Masereel and S. Schoenen for their help for follicular quantification. The authors acknowledge M. Dehuy, E. Konradowski, E. Feyereisen, and I. Dasoul for their excellent technical assistance.

The authors thank the Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS, Télévie, Belgium; 7.4597.12-7.4622.14-7.4590.16), the Fondation contre le Cancer (foundation of public interest, Belgium), the Fonds spéciaux de la Recherche (University of Liège), the Centre Anticancéreux près l’Université de Liège, the Fonds Léon Fredericq (University of Liège), the Direction Générale Opérationnelle de l’Economie, de l’Emploi et de la Recherche from the Service Public de Wallonie (SPW, Belgium), the Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium), the Plan National Cancer (Service Public Fédéral), and the Actions de Recherche Concertées (University of Liege, Belgium). The authors also thank the GIGA (Groupe Interdisciplinaire de Génoprotéomique Appliquée, University of Liege, Belgium) for the access to the GIGA-Imaging and Flow Cytometry platform and Dr. S. Ormenese and R. Stephan for their support with FACS analyses.

Author’s roles

MF performed experiments, interpreted data, and wrote the manuscript. LN contributed to in vitro experiments. LH and SL interpreted data and revised the manuscript. SB performed the computer images analysis. MN conceived and designed the study and corrected the manuscript. CM conceived and designed the study, interpreted data, corrected the manuscript, and substantially contributed to critical revisions. All authors read and approved the final manuscript.

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

The use of human follicular fluid and ovarian tissue was approved by the Ethics Committee of the CHR Citadelle, University of Liège (CE412/1508 and CE412/1448, respectively). The use of the xenograft model was approved by the Animal Ethics Committee of the University of Liège (Reference 1304, October 2012).

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10815_2018_1353_MOESM1_ESM.pdf (95 kb)
ESM 1 (PDF 95 kb)

References

  1. 1.
    Oktay K, Sonmezer M. Chemotherapy and amenorrhea: risks and treatment options. Curr Opin Obstet Gynecol. 2008;20(4):408–15.  https://doi.org/10.1097/GCO.0b013e328307ebad.CrossRefPubMedGoogle Scholar
  2. 2.
    Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y. Orthotopic and heterotopic ovarian tissue transplantation. Hum Reprod Update. 2009;15(6):649–65.  https://doi.org/10.1093/humupd/dmp021.CrossRefPubMedGoogle Scholar
  3. 3.
    Demeestere I, Simon P, Dedeken L, Moffa F, Tsepelidis S, Brachet C, et al. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod. 2015;30(9):2107–9.  https://doi.org/10.1093/humrep/dev128.CrossRefPubMedGoogle Scholar
  4. 4.
    Jensen AK, Macklon KT, Fedder J, Ernst E, Humaidan P, Andersen CY. 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children. J Assist Reprod Genet. 2016;34:325–36.  https://doi.org/10.1007/s10815-016-0843-9.CrossRefPubMedGoogle Scholar
  5. 5.
    Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377(17):1657–65.  https://doi.org/10.1056/NEJMra1614676.CrossRefPubMedGoogle Scholar
  6. 6.
    Van Eyck AS, Jordan BF, Gallez B, Heilier JF, Van Langendonckt A, Donnez J. Electron paramagnetic resonance as a tool to evaluate human ovarian tissue reoxygenation after xenografting. Fertil Steril. 2009;92(1):374–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Nugent D, Newton H, Gallivan L, Gosden RG. Protective effect of vitamin E on ischaemia-reperfusion injury in ovarian grafts. J Reprod Fertil. 1998;114(2):341–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Nisolle M, Casanas-Roux F, Qu J, Motta P, Donnez J. Histologic and ultrastructural evaluation of fresh and frozen-thawed human ovarian xenografts in nude mice. Fertil Steril. 2000;74(1):122–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Camboni A, Martinez-Madrid B, Dolmans MM, Nottola S, Van Langendonckt A, Donnez J. Autotransplantation of frozen-thawed ovarian tissue in a young woman: ultrastructure and viability of grafted tissue. Fertil Steril. 2008;90(4):1215–8.  https://doi.org/10.1016/j.fertnstert.2007.08.084.CrossRefPubMedGoogle Scholar
  10. 10.
    Israely T, Nevo N, Harmelin A, Neeman M, Tsafriri A. Reducing ischaemic damage in rodent ovarian xenografts transplanted into granulation tissue. Hum Reprod. 2006;21(6):1368–79.CrossRefPubMedGoogle Scholar
  11. 11.
    Abir R, Fisch B, Jessel S, Felz C, Ben Haroush A, Orvieto R. Improving posttransplantation survival of human ovarian tissue by treating the host and graft. Fertil Steril. 2011;95(4):1205–10.CrossRefPubMedGoogle Scholar
  12. 12.
    Shikanov A, Zhang Z, Xu M, Smith RM, Rajan A, Woodruff TK, et al. Fibrin encapsulation and vascular endothelial growth factor delivery promotes ovarian graft survival in mice. Tissue Eng Part A. 2011;17(23–24):3095–104.  https://doi.org/10.1089/ten.TEA.2011.0204.CrossRefPubMedGoogle Scholar
  13. 13.
    Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One. 2011;6(4):e19475.CrossRefPubMedGoogle Scholar
  14. 14.
    Labied S, Delforge Y, Munaut C, Blacher S, Colige A, Delcombel R, et al. Isoform 111 of vascular endothelial growth factor (VEGF111) improves angiogenesis of ovarian tissue xenotransplantation. Transplantation. 2013;95(3):426–33.  https://doi.org/10.1097/TP.0b013e318279965c.CrossRefPubMedGoogle Scholar
  15. 15.
    Commin L, Buff S, Rosset E, Galet C, Allard A, Bruyere P, et al. Follicle development in cryopreserved bitch ovarian tissue grafted to immunodeficient mouse. Reprod Fertil Dev. 2012;24(3):461–71.  https://doi.org/10.1071/RD11166.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang L, Ying YF, Ouyang YL, Wang JF, Xu J. VEGF and bFGF increase survival of xenografted human ovarian tissue in an experimental rabbit model. J Assist Reprod Genet. 2013;30(10):1301–11.  https://doi.org/10.1007/s10815-013-0043-9.CrossRefPubMedGoogle Scholar
  17. 17.
    Henry L, Labied S, Fransolet M, Kirschvink N, Blacher S, Noel A, et al. Isoform 165 of vascular endothelial growth factor in collagen matrix improves ovine cryopreserved ovarian tissue revascularisation after xenotransplantation in mice. Reprod Biol Endocrinol. 2015;13:12.  https://doi.org/10.1186/s12958-015-0015-2.CrossRefPubMedGoogle Scholar
  18. 18.
    Langbeen A, Ginneken CV, Fransen E, Bosmans E, Leroy JL, Bols PE. Morphometrical analysis of preantral follicular survival of VEGF-treated bovine ovarian cortex tissue following xenotransplantation in an immune deficient mouse model. Anim Reprod Sci. 2016;168:73–85.  https://doi.org/10.1016/j.anireprosci.2016.02.029.CrossRefPubMedGoogle Scholar
  19. 19.
    Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012;298:229–317.  https://doi.org/10.1016/B978-0-12-394309-5.00006-7.CrossRefPubMedGoogle Scholar
  20. 20.
    Liu J, Van der Elst J, Van den Broecke R, Dhont M. Early massive follicle loss and apoptosis in heterotopically grafted newborn mouse ovaries. Hum Reprod. 2002;17(3):605–11.CrossRefPubMedGoogle Scholar
  21. 21.
    Yang H, Lee HH, Lee HC, Ko DS, Kim SS. Assessment of vascular endothelial growth factor expression and apoptosis in the ovarian graft: can exogenous gonadotropin promote angiogenesis after ovarian transplantation? Fertil Steril. 2008;90(4 Suppl):1550–8.  https://doi.org/10.1016/j.fertnstert.2007.08.086.CrossRefPubMedGoogle Scholar
  22. 22.
    Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16(6):2129–44.CrossRefPubMedGoogle Scholar
  23. 23.
    Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation. 1998;97(3):276–81.CrossRefPubMedGoogle Scholar
  24. 24.
    Himi T, Ishizaki Y, Murota S. A caspase inhibitor blocks ischaemia-induced delayed neuronal death in the gerbil. Eur J Neurosci. 1998;10(2):777–81.CrossRefPubMedGoogle Scholar
  25. 25.
    Cursio R, Gugenheim J, Ricci JE, Crenesse D, Rostagno P, Maulon L, et al. Caspase inhibition protects from liver injury following ischemia and reperfusion in rats. Transpl Int. 2000;13(Suppl 1):S568–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Iwata A, Harlan JM, Vedder NB, Winn RK. The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemia-reperfusion injury: implication for clinical trials. Blood. 2002;100(6):2077–80.  https://doi.org/10.1182/blood-2002-03-0752.CrossRefPubMedGoogle Scholar
  27. 27.
    Azuara D, Sola A, Hotter G, Calatayud L, de Oca J. Apoptosis inhibition plays a greater role than necrosis inhibition in decreasing bacterial translocation in experimental intestinal transplantation. Surgery. 2005;137(1):85–91.  https://doi.org/10.1016/j.surg.2004.06.008.CrossRefPubMedGoogle Scholar
  28. 28.
    Emamaullee JA, Stanton L, Schur C, Shapiro AM. Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes. 2007;56(5):1289–98.  https://doi.org/10.2337/db06-1653.CrossRefPubMedGoogle Scholar
  29. 29.
    Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW, Cohen GM. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. Biochem J. 1996;315(Pt 1):21–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Henry L, Fransolet M, Labied S, Blacher S, Masereel MC, Foidart JM, et al. Supplementation of transport and freezing media with anti-apoptotic drugs improves ovarian cortex survival. J Ovarian Res. 2016;9(1):4.  https://doi.org/10.1186/s13048-016-0216-0.CrossRefPubMedGoogle Scholar
  31. 31.
    Zhang JM, Li LX, Yang YX, Liu XL, Wan XP. Is caspase inhibition a valid therapeutic strategy in cryopreservation of ovarian tissue? J Assist Reprod Genet. 2009;26(7):415–20.  https://doi.org/10.1007/s10815-009-9331-9.CrossRefPubMedGoogle Scholar
  32. 32.
    Shi FT, Cheung AP, Leung PC. Growth differentiation factor 9 enhances activin a-induced inhibin B production in human granulosa cells. Endocrinology. 2009;150(8):3540–6.  https://doi.org/10.1210/en.2009-0267.CrossRefPubMedGoogle Scholar
  33. 33.
    Fransolet M, Henry L, Labied S, Noël A, Nisolle M, Munaut C. In vitro evaluation of the anti-apoptotic drug Z-VAD-FMK on human ovarian granulosa cell lines for further use in ovarian tissue transplantation. J Assist Reprod Genet. 2015;32(10):1551–9.  https://doi.org/10.1007/s10815-015-0536-9.CrossRefPubMedGoogle Scholar
  34. 34.
    Gosden RG, Baird DT, Wade JC, Webb R. Restoration of fertility to oophorectomized sheep by ovarian autografts stored at −196 degrees C. Hum Reprod. 1994;9(4):597–603.CrossRefPubMedGoogle Scholar
  35. 35.
    Fransolet M, Henry L, Labied S, Masereel MC, Blacher S, Noel A, et al. Influence of mouse strain on ovarian tissue recovery after engraftment with angiogenic factor. J Ovarian Res. 2015;8(1):14.  https://doi.org/10.1186/s13048-015-0142-6.CrossRefPubMedGoogle Scholar
  36. 36.
    Aubard Y, Piver P, Cogni Y, Fermeaux V, Poulin N, Driancourt MA. Orthotopic and heterotopic autografts of frozen-thawed ovarian cortex in sheep. Hum Reprod. 1999;14(8):2149–54.CrossRefPubMedGoogle Scholar
  37. 37.
    Tilly JL, Kolesnick RN. Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. Biochim Biophys Acta. 2002;1585(2–3):135–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Baird DT, Webb R, Campbell BK, Harkness LM, Gosden RG. Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at −196 C. Endocrinology. 1999;140(1):462–71.  https://doi.org/10.1210/en.140.1.462.CrossRefPubMedGoogle Scholar
  39. 39.
    Rimon E, Cohen T, Dantes A, Hirsh L, Amit A, Lessing JB, et al. Apoptosis in cryopreserved human ovarian tissue obtained from cancer patients: a tool for evaluating cryopreservation utility. Int J Oncol. 2005;27(2):345–53.PubMedGoogle Scholar
  40. 40.
    Fauque P, Ben Amor A, Joanne C, Agnani G, Bresson JL, Roux C. Use of trypan blue staining to assess the quality of ovarian cryopreservation. Fertil Steril. 2007;87(5):1200–7.  https://doi.org/10.1016/j.fertnstert.2006.08.115.CrossRefPubMedGoogle Scholar
  41. 41.
    Xiao Z, Wang Y, Li L, Li SW. Cryopreservation of the human ovarian tissue induces the expression of Fas system in morphologically normal primordial follicles. Cryo Letters. 2010;31(2):112–9.PubMedGoogle Scholar
  42. 42.
    Hussein MR. Apoptosis in the ovary: molecular mechanisms. Hum Reprod Update. 2005;11(2):162–77.  https://doi.org/10.1093/humupd/dmi001.CrossRefPubMedGoogle Scholar
  43. 43.
    Isachenko V, Mallmann P, Petrunkina AM, Rahimi G, Nawroth F, Hancke K, et al. Comparison of in vitro- and chorioallantoic membrane (CAM)-culture systems for cryopreserved medulla-contained human ovarian tissue. PLoS One. 2012;7(3):e32549.  https://doi.org/10.1371/journal.pone.0032549.CrossRefPubMedGoogle Scholar
  44. 44.
    Stroh C, Cassens U, Samraj AK, Sibrowski W, Schulze-Osthoff K, Los M. The role of caspases in cryoinjury: caspase inhibition strongly improves the recovery of cryopreserved hematopoietic and other cells. FASEB J. 2002;16(12):1651–3.  https://doi.org/10.1096/fj.02-0034fje.CrossRefPubMedGoogle Scholar
  45. 45.
    Gururajan R, Lahti JM, Kidd VJ. Molecular analysis of programmed cell death in mammals. In: Adolph KW, editor. Human genome methods. New York, CRC Press; 1998. p. 135–157.Google Scholar
  46. 46.
    Roness H, Gavish Z, Cohen Y, Meirow D. Ovarian follicle burnout: a universal phenomenon? Cell Cycle. 2013;12(20):3245–6.  https://doi.org/10.4161/cc.26358.CrossRefPubMedGoogle Scholar
  47. 47.
    Silber S. Ovarian tissue cryopreservation and transplantation: scientific implications. J Assist Reprod Genet. 2016;33:1595–603.  https://doi.org/10.1007/s10815-016-0814-1.CrossRefPubMedGoogle Scholar
  48. 48.
    Gavish Z, Spector I, Peer G, Schlatt S, Wistuba J, Roness H, et al. Follicle activation is a significant and immediate cause of follicle loss after ovarian tissue transplantation. J Assist Reprod Genet. 2017;35:61–9.  https://doi.org/10.1007/s10815-017-1079-z.CrossRefPubMedGoogle Scholar
  49. 49.
    Kong HS, Kim SK, Lee J, Youm HW, Lee JR, Suh CS, et al. Effect of exogenous anti-Mullerian hormone treatment on cryopreserved and transplanted mouse ovaries. Reprod Sci. 2016;23(1):51–60.  https://doi.org/10.1177/1933719115594021.CrossRefPubMedGoogle Scholar
  50. 50.
    Ayuandari S, Winkler-Crepaz K, Paulitsch M, Wagner C, Zavadil C, Manzl C, et al. Follicular growth after xenotransplantation of cryopreserved/thawed human ovarian tissue in SCID mice: dynamics and molecular aspects. J Assist Reprod Genet. 2016;33:1585–93.  https://doi.org/10.1007/s10815-016-0769-2.CrossRefPubMedGoogle Scholar
  51. 51.
    Hancke K, Walker E, Strauch O, Gobel H, Hanjalic-Beck A, Denschlag D. Ovarian transplantation for fertility preservation in a sheep model: can follicle loss be prevented by antiapoptotic sphingosine-1-phosphate administration? Gynecol Endocrinol. 2009;25(12):839–43.  https://doi.org/10.3109/09513590903159524.CrossRefPubMedGoogle Scholar
  52. 52.
    Martinez-Madrid B, Donnez J, Van Eyck AS, Veiga-Lopez A, Dolmans MM, Van Langendonckt A. Chick embryo chorioallantoic membrane (CAM) model: a useful tool to study short-term transplantation of cryopreserved human ovarian tissue. Fertil Steril. 2009;91(1):285–92.  https://doi.org/10.1016/j.fertnstert.2007.11.026.CrossRefPubMedGoogle Scholar
  53. 53.
    Lee JR, Youm HW, Kim SK, Jee BC, Suh CS, Kim SH. Effect of necrostatin on mouse ovarian cryopreservation and transplantation. Eur J Obstet Gynecol Reprod Biol. 2014;178:16–20.  https://doi.org/10.1016/j.ejogrb.2014.04.040.CrossRefPubMedGoogle Scholar
  54. 54.
    Gong JS, Kim GJ. The role of autophagy in the placenta as a regulator of cell death. Clin Exp Reprod Med. 2014;41(3):97–107.  https://doi.org/10.5653/cerm.2014.41.3.97.CrossRefPubMedGoogle Scholar
  55. 55.
    Adhikari D, Liu K. mTOR signaling in the control of activation of primordial follicles. Cell Cycle. 2010;9(9):1673–4.  https://doi.org/10.4161/cc.9.9.11626.CrossRefPubMedGoogle Scholar
  56. 56.
    McLaughlin M, Patrizio P, Kayisli U, Luk J, Thomson TC, Anderson RA, et al. mTOR kinase inhibition results in oocyte loss characterized by empty follicles in human ovarian cortical strips cultured in vitro. Fertil Steril. 2011;96(5):1154–9 e1.  https://doi.org/10.1016/j.fertnstert.2011.08.040.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Laboratory of Tumor and Developmental Biology, GIGA-RUniversity of LiègeLiègeBelgium
  2. 2.Department of Gynecology and Obstetrics, CPMAUniversity of LiègeLiègeBelgium

Personalised recommendations